The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Longitudinal changes in patient-reported outcomes (PROs) among early phase cancer clinical trial (EP-CT) participants.
 
Debra Lundquist
No Relationships to Disclose
 
Andrea Pelletier
No Relationships to Disclose
 
Sienna Durbin
No Relationships to Disclose
 
Laura A. Petrillo
No Relationships to Disclose
 
Rachel Jimenez
Employment - Biogen (I)
Stock and Other Ownership Interests - Biogen (I)
 
Victoria Turbini
No Relationships to Disclose
 
Anh B. Lam
No Relationships to Disclose
 
Viola Bame
No Relationships to Disclose
 
Kaitlyn Lynch
No Relationships to Disclose
 
Vaishnavi Reddy Yalala
No Relationships to Disclose
 
Nicholas Ollila
No Relationships to Disclose
 
Benjamin Malowitz
No Relationships to Disclose
 
Casandra McIntyre
Consulting or Advisory Role - Putnam Associates
 
Dejan Juric
Stock and Other Ownership Interests - PIC Therapeutics; Relay Therapeutics; Vibliome Therapeutics
Consulting or Advisory Role - AstraZeneca; Eisai; Genentech; Lilly; MapKure; Novartis; Pfizer; PIC Therapeutics; Relay Therapeutics; Vibliome Therapeutics
Research Funding - Amgen (Inst); Arvinas (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Eisai (Inst); Genentech (Inst); Infinity Pharmaceuticals (Inst); Infinity Pharmaceuticals (Inst); InventisBio (Inst); Novartis (Inst); Pfizer (Inst); Ribon Therapeutics (Inst); Scorpion Therapeutics; Syros Pharmaceuticals (Inst); Takeda (Inst); Takeda (Inst)
 
Ryan David Nipp
No Relationships to Disclose